Clinical trials: B-Cell Neoplasm
B-cell Tumors
A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects
This study used a single-dose, open and fixed sequence design to compare the pharmacokinetics in healthy subjects.
- Trial name
- NCT05560360
- Testing
- SHR1459 tablet, Efavirenz tablet
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Acute Lymphoblastic Leukemia
Assesment of JL1 Expression in Acute Leukemia
The aim of this study is to assess JL1 expression by flow cytometric immunophenotyping in patients with B-cell Acute Lymphoblastic Leukemia (ALL) and to correlate it with clinical, morphological, immunophenotypic, cytogenetic…
- Trial name
- NCT04554381
- Testing
- JL1 antigen
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Systemic Lupus Erythematosus, BAFF Polymorphism
BAFF and APRIL and RESPONSE TO BELIMUMAB in SLE
This project is intended to identify the routes on which BAFF and APRIL act in order to detect possible future candidates to Belimumab treatment among patients diagnosed of SLE.
- Trial name
- BAFF (NCT03919643)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Diffuse Large B-cell Lymphoma(DLBCL)
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression
Zanubrutinib is a highly specific, potent new Bruton's tyrosine kinase （BTK） inhibitor, with minimal off-target inhibition of other kinases.
- Trial name
- NCT05189197
- Testing
- Zanubrutinib + R-CHOP
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Fudan University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 747 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer, Chronic Lymphocytic Leukemia
Time Restricted Eating in Haematological Malignancies
The goal of this clinical trial is to learn if time restricted eating (TRE), a form of intermittent fasting, can impact health outcomes in patients with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06862323
- Testing
- Time-Restricted Eating
- Where
- Canada
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent Non-hodgkin Lymphoma
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic…
- Trial name
- NCT05876923
- Testing
- Biospecimen Collection, Cardiopulmonary Exercise Testing, Dual X-ray Absorptiometry
- Where
- 2 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Multiple Myeloma
Serum Soluble BCMA as a Non-Invasive Marker in Multiple Myeloma
This prospective study aims to investigate serum soluble B-cell maturation antigen (sBCMA) as a non-invasive marker in patients with multiple myeloma and to compare its levels with healthy controls.
- Trial name
- NCT07855718
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
Communication Skills Intervention to Promote Transition Into Survivorship
The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship.
- Trial name
- NCT01483664
- Where
- 9 sites in United States
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia
Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)
The aim of this proposal is to identify immune biomarkers, genetic risk, and the clinical consequences of low count monoclonal B-cell lymphocytosis (LC MBL), a common premalignant condition affecting up to 17% of European adults…
- Conditions
- Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia, Infections, Cancers
- Trial name
- MBL RiskConseq (NCT06416267)
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Haifa
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
The primary objectives of this study are to determine the maximum tolerated dose (MTD) or optimal biologic dose (OBD) and safety profile of CAT-8015 in participants with relapsed or refractory advanced B-cell NHL (diffuse large…
- Trial name
- NCT01030536
- Testing
- CAT-8015 20 mcg/kg, CAT-8015 30 mcg/kg, CAT-8015 40 mcg/kg
- Where
- 8 sites in United States, Poland
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Healthy Participants
A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants
The purpose of this study is to investigate the absorption, the metabolic pathways and the excretion of ibrutinib in healthy male adult participants after administration of a single oral dose of 50 mg to 140 mg (5 mg/mL solution)…
- Trial name
- NCT01674322
- Testing
- Ibrutinib
- Where
- Belgium
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Body Mass Index 25 or Greater, BRCA1 Gene Mutation
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
This pilot clinical trial studies different types of energy balance interventions to see how well they work in increasing the physical activity levels of breast cancer gene-positive patients, Lynch syndrome-positive patients…
- Conditions
- Body Mass Index 25 or Greater, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Carcinoma
- Trial name
- NCT02194387
- Testing
- Dietary Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Waldenström Macroglobulinemia
Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia
Waldenström's macroglobulinemia is a rare disease whose pathophysiology remains at present poorly understood, although a recurrent mutation (L265P MYD88) has recently been described.
- Trial name
- WAL-KU (NCT02640287)
- Testing
- Blood or bone marrow samples
- Where
- France
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Follicular Lymphoma
Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma
The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and Prednisone) in a population of patients with follicular…
- Trial name
- R2-CHOP2 (NCT01393756)
- Testing
- Lenalidomide and R-CHOP
- Where
- 24 sites in France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The Lymphoma Academic Research Organisation
Diffuse Large B-cell Lymphoma
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL
The purpose of the study is to evaluate feasibility and efficacy of rituximab-bendamustine (R-B)combination in elderly patients affected by diffuse large B-cell lymphoma and defined as frail according to CGA.
- Trial name
- NCT01990144
- Testing
- Bendamustine+Rituximab
- Where
- 52 sites in Italy
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Acute Lymphoblastic Leukemia ALL, Chronic Lymphocytic Leukemia (CLL)
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia
aim of the work 1. To evaluate the presence of SF3B1-K700E mutation in acute lymphoblastic leukemia and chronic lymphocytic leukemia. 2.
- Trial name
- NCT07113132
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Safaa Ali
Acute Leukemia, Acute Lymphoblastic Leukemia
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies).
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT04195633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Malaria, Diabetes Mellitus
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Non-communicable diseases (NCDs) such as diabetes are increasing in countries where malaria transmission is common. This study aims to investigate the relationship between NCDs and parasitic infections in Cameroon.
- Conditions
- Malaria, Diabetes Mellitus, Metabolic Syndrome, Endemic
- Trial name
- NCT06278181
- Where
- Cameroon
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Failure
- Trial name
- NCT03622788
- Testing
- Anti-Thymocyte Globulin, Cyclophosphamide, Cytokine-treated Veto Cells
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center